P. Oleksy

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Jordan M. Graff, Michael B. Goldstein, Khoi D. Tran, 2022, The Lancet.

The efficacy of ranibizumab in idiopathic choroidal neovascularization – a case series report

P. Oleksy, 2017 .

Management of diffuse choroidal hemangioma in Sturge-Weber syndrome with Ruthenium-106 plaque radiotherapy

B. Romanowska-Dixon, A. Kubicka-Trząska, I. Karska-Basta, 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.

Arthur D. Fu, Ajay E. Kuriyan, Rishi P. Singh, 2022, Lancet.

The relationship between pre-pregnancy BMI, gestational weight gain and neonatal birth weight: a retrospective cohort study.

H. Huras, Katarzyna Marszalek, M. Radoń-Pokracka, 2019, Ginekologia polska.

Regional Identity, Separatism, and War in Eastern Europe: Donbass and Pridnestrovie

P. Oleksy, Marta Studenna-Skrukwa, 2019, Kultura i Społeczeństwo.

Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration.

P. Kaiser, F. Holz, S. Schmitz-Valckenberg, 2021, Ophthalmology.

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

R. Shah, P. Campochiaro, S. Gupta, 2023, Japanese Journal of Ophthalmology.

Faricimab Treat-and-Extend for Diabetic Macular Edema: 2-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.

P. Campochiaro, C. Regillo, D. Rosberger, 2023, Ophthalmology.